From the Document: "In 2018, the U.S. Trade Representative (USTR) determined, pursuant to an investigation under 'Section 301' (Title III of the Trade Act of 1974, 19 U.S.C. [United States Code] §§2411-2420), that China's acts, policies, and practices related to technology transfer, intellectual property (IP), and innovation were unreasonable or discriminatory and burdened or restricted U.S. commerce. In order to counter them and obtain their elimination, the Trump Administration used Section 301 authorities to impose four rounds of increased tariffs on about two-thirds of U.S. imports from China. However, to avoid harm to U.S. interests, the USTR introduced a new policy allowing stakeholders to request 'tariff exclusions' for U.S. imports that would otherwise have been subject to tariffs. Some policymakers and stakeholders have raised concerns about the implementation of the exclusion request process. [...] The Biden Administration continues to review its trade strategy for China. Actions by the USTR during 2021 and early 2022 were not aimed at providing broader tariff relief. They were limited to extending unexpired exclusions on medical supplies relevant to combatting the COVID-19 [coronavirus disease 2019] pandemic and reinstating certain exclusions that were previously extended. In May 2022, the agency announced a review of all Section 301 actions against China."
CRS In Focus, IF11582
Congressional Research Service: https://crsreports.congress.gov/